Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Thoracic 5Gastrointestinal 5Head & Neck 3Breast 3Genitourinary 2Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Melanoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lung Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1

Interventions

pembrolizumab 18Nivolumab 6Radiotherapy 5Paclitaxel 5Trastuzumab 4Specimen Handling 4Ipilimumab 4tisotumab vedotin 3temsirolimus 3olaparib 3lenvatinib 3X-Rays 3Taxes 3Surveys and Questionnaires 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3spartalizumab 2sargramostim 2rucaparib 2palbociclib 2fludarabine 2epacadostat 2enzalutamide 2durvalumab 2cabozantinib 2atezolizumab 2aflibercept 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Cetuximab × Genitourinary × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡